Atrial functional mitral regurgitation: Surgery improves outcomes more than medical therapy alone

Treating atrial functional mitral regurgitation (AFMR) with surgery may be more beneficial than medical therapy alone, according to new data published in JAMA Network Open.[1]

Medical images of "normal" functional mitral regurgitation, atrial functional mitral regurgitation (AFMR) and ventriculogenic functional mitral regurgitation (VFMR) courtesy of Zoghbi et al. and JACC: Cardiovascular Imaging. Read more here: https://doi.org/10.1016/j.jcmg.2022.08.016.

"These findings underscore the importance of understanding AFMR and its treatment options," one cardiologist said.

TAVR planning with valve-sizing software: GE Healthcare tech easier to use than competition

TAVR planning software with GE Healthcare's Valve Assist 2 technology.

Valve Assist 2 images courtesy of GE Healthcare, Butter et al, Journal of Cardiovascular Imaging.

Planning ahead of TAVR procedures with semi-automated sizing software helps cardiologists match each patient with the best device possible; not undersized or oversized, but something in the middle that would make Goldilocks proud.

Cardiologists detail world’s first implant of new device for ‘no-option’ chest pain patients

Interventional cardiologists in Canada have performed the world’s first implant of a new coronary sinus reducer designed to treat chest pain patients who see no benefits from other available interventional or surgical treatments. The A-Flux Reducer System was designed and developed by VahatiCor, a new medical device company associated with California-based T45 Labs.

Post-implant angiography results confirming a successful implant of the A-Flux Reducer System in a patient's coronary sinus to reduce angina. Image courtesy of EuroIntervention and Paradis et al.

The A-Flux Reducer System by VahatiCor was designed to “conform seamlessly” to any patient’s anatomy, and it can be repositioned or retrieved as necessary.